A carregar...
The Three P's: Parotid, PD-L1, and Pembrolizumab
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
Na minha lista:
| Publicado no: | Case Rep Oncol Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594310/ https://ncbi.nlm.nih.gov/pubmed/31308983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/2305315 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|